Tacrolimus restores podocyte injury and stabilizes the expression of Cabin1 in 5/6 nephrectomized rats

References

• Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis. J Int Med Res. 2009;37:892–898.
   PubMed Web of Science ®Google Scholar
• Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;38:1202–1211.
   Web of Science ®Google Scholar
• Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-Inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis. 2009;53:26–32.
   PubMed Web of Science ®Google Scholar
• Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694–3701.
   PubMed Web of Science ®Google Scholar
• Tang S, Leung JC, Chan LY, et al. Mycophe-nolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68:802–812.
   PubMed Web of Science ®Google Scholar
• Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004;19:3062–3067.
   PubMed Web of Science ®Google Scholar
• Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:281–287.
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14:931–938.
   PubMed Web of Science ®Google Scholar
• Li JS, Chen X, Peng L, et al. Angiopoietin-like-4, a potential target of Tacrolimus, predicts earlier podocyte injury in minimal change disease. PLoS One. 2015;10:e0137049.
   Google Scholar
• Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17:1304–1309.
   PubMed Web of Science ®Google Scholar
• Ozbay LA, Moller N, Juhl C, et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol. 2012;73:536–545.
   PubMed Web of Science ®Google Scholar
• Hammond DR, Udvadia AJ. Cabin1 expression suggests roles in neuronal development. Dev Dyn. 2010;239:2443–2451.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang Z, Liu L, Zhang Y, Zhou P, Liang J. Cabin1 localizes in glomerular podocyte and undergoes nuclear translocation during podocyte injury. Ren Fail. 2015;37:1344–1348.
   PubMed Web of Science ®Google Scholar
• Wen Y, Zhou P, Liu L, Wang Z, Zhang Y, Liang J. Effect of the knockdown of Cabin1 on p53 in glomerular podocyte. J Recept Signal Transduct Res. 2015;23:1–8.
   Google Scholar
• Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS. Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol. 2014;25:2916–2925.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Shi SF, Zhu L, et al. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol. 2012;35:312–320.
   PubMed Web of Science ®Google Scholar
• Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis. 2009;54:51–58.
   PubMed Web of Science ®Google Scholar
• Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol. 2010;25:1117–1124.
   PubMed Web of Science ®Google Scholar
• Lim SW, Jin L, Piao SG, Chung BH, Yang CW. Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. Lab Invest. 2015;95:1174–1185.
   PubMed Web of Science ®Google Scholar
• Liao R, Liu Q, Zheng Z, et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 2015;10:e0132724.
   PubMed Web of Science ®Google Scholar
• Shengyou Y, Li Y, Zhihong H, Yuanyuan M. Influence of tacrolimus on podocyte injury inducted by angiotensin II. J Renin Angiotensin Aldosterone Syst. 2015;16:260–266.
   PubMed Web of Science ®Google Scholar
• Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 2000;97:1196–1201.
   PubMed Web of Science ®Google Scholar
• Lai MM, Luo HR, Burnett PE, Hong JJ, Snyder SH. The calcineurin-binding protein cain is a negative regulator of synaptic vesicle endocytosis. J Biol Chem. 2000;275:34017–34020.
   PubMed Web of Science ®Google Scholar
• Yi JK, Kim HJ, Yu DH, et al. Regulation of inflammatory responses and fibroblast-like synoviocyte apoptosis by calcineurin-binding protein 1 in mice with collagen-induced arthritis. Arthritis Rheum. 2012;64:2191–2200.
   PubMed Web of Science ®Google Scholar
• Wang L, Chang JH, Paik SY, Tang Y, Eisner W, Spurney RF. Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol. 2011;25:1376–1386.
   PubMed Web of Science ®Google Scholar
• Fan P, Anthony R, Means J, Liu O. Calmodulin-dependent protein kinase IV regulates nuclear export of Cabin1 during T-cell activation. Embo J. 2005;24:2104–2113.
   PubMed Web of Science ®Google Scholar
• Jang H, Choi SY, Cho EJ, Youn HD. Cabin1 restrains p53 activity on chromatin. Nat Struct Mol Biol. 2009;16:910–915.
   PubMed Web of Science ®Google Scholar
• Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol. 2013;14:1084–1092.
   PubMed Web of Science ®Google Scholar
• Nijenhuis T, Sloan AJ, Hoenderop JG, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179:1719–1732.
   PubMed Web of Science ®Google Scholar
• Zhang B, Shi W, Ma J, et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl). 2012;90:1407–1420.
   PubMed Web of Science ®Google Scholar